Donaldson Sets Q4 Sales and EPS Records

Donaldson (DCI) posted robust Q4 and record full-year fiscal 2025 results, with Q4 sales up 5% to $981 million and adjusted EPS up 10% to $1.03, while full-year revenue hit $3.7 billion and operating margin reached a record 15.7%. The company achieved a record 16.4% operating margin in Q4 through stringent cost discipline, restructuring, and pricing power, effectively offsetting LIFO inventory cost pressures. Growth was significantly driven by its aftermarket business, which saw mobile solutions exceed $1 billion in annual sales, and increased penetration of higher-margin replacement parts and connected solutions. Despite a delayed revenue ramp for bioprocessing to fiscal 2027, DCI issued strong fiscal 2026 guidance, targeting record earnings of $4.00 per share and continued operating margin expansion, signaling a strategic focus on resilient, high-margin revenue streams and ongoing shareholder returns.

Analysis

Donaldson (DCI) reported a robust fiscal 2025, achieving record full-year revenue of $3.7 billion and culminating in a strong fourth quarter with sales up 5% to $981 million and adjusted EPS rising 10% to $1.03. A key highlight is the company's operational execution, which drove a record Q4 operating margin of 16.4% despite significant gross margin pressure from LIFO inventory costs tied to U.S.-China tariffs. This was accomplished through stringent cost discipline, as evidenced by a 160-basis-point improvement in operating expenses as a percentage of sales. Growth was primarily fueled by a strategic focus on higher-margin, recurring revenue, with the mobile solutions aftermarket business surpassing $1 billion in annual sales and the industrial segment deriving nearly 50% of quarterly sales from replacement parts. While this aftermarket strength provides resilience, management was transparent about headwinds in new growth areas, specifically noting that the revenue ramp from its bioprocessing investments is delayed until fiscal 2027. The company's confident outlook is underscored by its fiscal 2026 guidance, which projects record EPS of up to $4.08, continued operating margin expansion, and a shareholder return plan that includes repurchasing 2%-3% of outstanding shares.

Key Decisions for Investors

• Investors should weigh the company's proven operational execution and margin resilience, driven by its successful shift to aftermarket sales, which mitigates exposure to cyclical first-fit equipment markets.
• The strong fiscal 2026 guidance for record earnings and operating margin expansion provides a clear positive catalyst, though the projected 3% sales growth at the midpoint suggests the investment thesis is centered on profitability rather than aggressive top-line expansion.
• Factor in the delayed revenue contribution from the bioprocessing division, now expected in fiscal 2027, which requires patience for this long-term growth catalyst to materialize.
• Consider the robust capital return program, including a planned 2%-3% share repurchase, as a key component of the total shareholder return thesis and a signal of management's confidence in the business outlook.